This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Hengeveld PJ, Levin MD, Kolijn PM, Langerak AW. Reading the B-cell receptor immunome in chronic lymphocytic leukemia: revelations and applications. Exp Hematol. 2021;93:14–24.
Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, et al. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood. 2021;137:1365–76.
Sutton LA, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, et al. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica. 2016;101:959–67.
Jaramillo Sonia, Agathangelidis Andreas, Schneider Christof, Bahlo Jasmin, Robrecht Sandra, Tausch Eugen, et al. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). Haematologica. 2019;105:2598–607.
Maity PC, Bilal M, Koning MT, Young M, Van Bergen CAM, Renna V, et al. IGLV3-21∗01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. Proc Natl Acad Sci USA. 2020;117:4320–7.
Nadeu F, Royo R, Clot G, Duran-Ferrer M, Navarro A, MartÃn S, et al. IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood. 2021;137:2935–46.
Minici C, Gounari M, Übelhart R, Scarfò L, Dühren-von Minden M, Schneider D, et al. Distinct homotypic B-cell receptor interactions shape the outcome of chronic lymphocytic leukaemia. Nat Commun. 2017;8:1–12.
Kolijn PM, Saberi Hosnijeh F, Späth F, Hengeveld PJ, Agathangelidis A, Saleh M, et al. High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis. Blood. 2021;139:1557–63.
Kolijn PM, Muggen AF, Ljungström V, Agathangelidis A, Wolvers-Tettero ILM, Beverloo HB, et al. Consistent B cell receptor immunoglobulin features between siblings in familial chronic lymphocytic leukemia. Front Oncol. 2021;11:1–11.
Kersting S, Dubois J, Nasserinejad K, Dobber JA, Mellink C, van der Kevie-Kersemaekers A-MF, et al. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet Haematol. 2022;9:e190–9.
Levin MD, Kater A, Mattsson M, Kersting S, Ranti J, Thi Tuyet Tran H, et al. Protocol description of the HOVON 141/VISION trial: A prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL). BMJ Open. 2020;10:1–5.
Niemann CU, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, et al. Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) - 15-month safety, response and mrd evaluation: third interim analysis from the phase II vision HO141 trial. Blood. 2019;134:4292–4292.
Leeksma AC, Baliakas P, Moysiadis T, Puiggros A, Plevova K, van der Kevie-Kersemaekers AM, et al. Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: A multi-center study. Haematologica. 2020;105:87–97.
Darzentas N, Hadzidimitriou A, Murray F, Hatzi K, Josefsson P, Laoutaris N, et al. A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: Molecular and computational evidence. Leukemia. 2010;24:125–32.
Acknowledgements
The authors would like to thank all patients, their families, and investigators involved in the HOVON-139/GIVE and HOVON-141/VIsion trials. In addition, the authors would like to acknowledge Mr. Jorn Assmann and Miss. Lina van der Straten for their participation in constructive discussions that have significantly improved the manuscript.
Funding
The HOVON-139/GIVE trial was funded by F Hoffmann-La Roche (ML29995), who had the opportunity to review and comment on this paper. The HOVON-141/VIsion trial was supported by AbbVie and Janssen/Pharmacyclics, who had the opportunity to review and comment on this paper. In addition, the HOVON-141/VIsion trial was funded by the Novo Nordisk Foundation grant NNF160C0019302.
Author information
Authors and Affiliations
Contributions
PJH, MDL, and AWL conceived of the study. PJH and YEE performed the light chain sequencing. JMND, SK, CUN, APK, and MDL were involved in designing, operating and biobanking the HOVON-139/GIVE and/or HOVON-141/VIsion trials and facilitated the availability of the samples. CHMM, AMvdKK, ORFM, and MMM performed and analyzed the genomic array and targeted NGS analysis. LME performed the heavy-chain sequencing. KH assisted in primer design. PMK contributed to the data analysis. PJH, MDL, AWL, PMK, and PEW interpreted and reviewed the data. PJH, MDL, and AWL wrote the manuscript. All authors critically read and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Competing interests
SK has received personal fees from Janssen, AbbVie, Novartis, Gilead, and Celgene; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. CUN received research funding and/or consultancy fees from Abbvie, AstraZeneca, Roche, Janssen, CSL Behring, Takeda, and Octapharma. APK has received personal fees from AbbVie, LAVA, Genmab, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb; and research funding from AbbVie, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb. AWL has received research support via an unrestricted grant from Roche-Genentech and a speaker-fee from Janssen. M-DL has received personal fees from AbbVie, Janssen, and Roche; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. All other authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hengeveld, P.J., Ertem, Y.E., Dubois, J.M.N. et al. Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110. Leukemia 36, 1935–1938 (2022). https://doi.org/10.1038/s41375-022-01600-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-022-01600-6